Lime Delivers Record Revenue and Profitability, Positive Free Cash Flow in 2024
18.2.2025 12:00:00 CET | Business Wire | Press release
Global Micromobility Leader’s Business Momentum Delivers Profitable GrowthGross Bookings of $810 Million, Net Revenue of $686 MillionAdjusted EBITDA Exceeds $140 Million, Up From $94 Million in 2023Free Cash Flow Positive for Second Consecutive Year
Lime, the world’s largest shared electric vehicle company, today announced record unaudited financial results for 2024, reflecting continued operating and financial momentum as the Company executes against its mission to build a future where transportation is shared, affordable and carbon-free.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218624910/en/
Two young women ride Lime electric bikes through a city. (Photo: Business Wire)
Full Year 2024 Financial Highlights (unaudited)
- Gross bookings of $810 million, reflecting growth of 31% versus 2023
- Net revenue of $686 million, an increase of 32% compared to 2023
- Fourth consecutive year of 30%+ topline growth
- Adjusted EBITDA1 over $140 million, up from $94 million in 2023, representing year-over-year growth of 49%
- Adjusted EBITDA margin1 over 20%, representing more than 200 basis points of expansion versus prior year
- Free cash flow positive for second consecutive year
“2024 was an exceptional year for Lime and our global leadership is evident both operationally and financially with strong results across all of our key metrics,“ said Wayne Ting, CEO. “We grew profits faster than revenue in 2024, posting another record year of results through serving more than 24 million riders in hundreds of communities around the world and bringing Lime to more cities globally. As we continue to expand our fleet, our permit win and retention rates demonstrate that Lime remains the clear choice for cities seeking to reduce traffic congestion and meet carbon emission goals. While we saw record demand in 2024, we’re just scratching the surface of micromobility’s potential to transform cities and better connect people. Our proven execution, combined with these global tailwinds, position Lime for durable growth for years to come.”
Full Year 2024 Operating Highlights and Metrics
- Provided more than 200 million rides in 2024, up 30% from 2023, equating to more than six rides per second, with more than 24 million riders taking a trip in 2024
- Surpassed 750 million lifetime rides
- Won over 90% of competitive permits to operate in top tier cities
- Expanded to more than 20 new cities globally, including launches into two new countries, Japan and Greece
- Expanded average operational fleet by nearly 20% to over 270,000 vehicles globally
Lime also deepened its management team in 2024, with key executive appointments who draw on decades of experience at Fortune 500 companies. Chief Legal Officer Susie Giordano brings more than 30 years of experience in capital markets, governance, compliance and M&A, including serving as the Corporate Secretary for Intel Corporation. Incoming Chief Technology Officer Jon Jenkins joined Lime from Amazon, with prior roles including Head of Engineering at Pinterest.
“As we continue to advance our mission, we are driving consistent growth through fleet expansion, increased rider utilization, geographic expansion and continuous innovation,” said Ann Gugino, CFO. “We are well above a ‘rule of 40’ company and are intently focused on scaling our unit economics. In 2024, we invested for growth, while simultaneously delivering increased profitability and positive free cash flow. Importantly, our team has a proven track record of strong execution and Lime has an exciting roadmap and multiple avenues for growth in 2025 and beyond.”
Environmental sustainability remains a key focus for Lime and it continues to make an impact on reducing carbon emissions in cities. Last year, riders avoided an estimated 20,000 metric tons of CO2 emissions, spared an estimated 2.2 million gallons of gas (8.5M liters) from being consumed and replaced more than an estimated 43 million car trips with two-wheeled, emissions-free rides. Lime also continues to make meaningful strides in reducing its own carbon intensity across Scopes 1, 2 and 3 emissions. Its most recent carbon inventory measuring 2023 impact showed a 59.5% reduction from its 2019 baseline. Lime plans to release its 2024 carbon inventory later this spring.
About Lime
Lime’s mission is to build a future where transportation is shared, electric and carbon-free. As a leading global provider of shared electric vehicles, Lime partners with cities to deploy electric bikes and scooters to serve any trip under five miles. A Time Magazine 100 Most Influential Companies and Fast Company Brand that Matters, Lime has powered more than 750 million rides across five continents, spurring a new generation of clean alternatives to car ownership. Learn more at li.me.
_____________________
1 The company’s unaudited financial results communicated herein reflect certain non-GAAP financial measures. In particular, the Company presents adjusted EBITDA which is defined as earnings before interest, income taxes, depreciation and amortization, and excludes certain items that affect comparability from period to period or are not indicative of our ongoing operating performance, and Adjusted EBITDA margin, which is calculated as Adjusted EBITDA/Net Revenue. The non-GAAP financial measures provided in this press release are not a substitute for the company’s financial results prepared in accordance with U.S. GAAP and may be different from similarly-titled non-GAAP measures used by other companies. Unaudited financial results communicated herein are subject to change upon finalization of the audit.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218624910/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom